Article: [Efficacy of Urapidil in treating lower urinary tract symptoms in patients with benign prostatic hyperplasia: A systematic review and meta-analysis].
Zhonghua nan ke xue = National journal of andrology
2024 Volume 29, Issue 6, Page(s) 538–542
Abstract: Objective: To investigate the potential application of α-1 blocker (urapidil) in the treatment of lower urinary tract symptoms (LUTS) in male patients with benign prostatic hypertrophy (BPH), we conducted a comprehensive meta-analysis.: Methods: Our ... ...
Abstract | Objective: To investigate the potential application of α-1 blocker (urapidil) in the treatment of lower urinary tract symptoms (LUTS) in male patients with benign prostatic hypertrophy (BPH), we conducted a comprehensive meta-analysis. Methods: Our study involved identifying and collecting randomized controlled trials (RCT) and clinical observational studies from databases including PubMed、MEDLINE、Web of science、CNKI and Wanfang database. We performed meta-analysis using RevMan 5.2.0 software for both fixed effects model and random effects model. Results: Our analysis included 3 short-term (within 1 month) observational studies and 1 RCT involving 142 patients. We found that urapidil significantly improved the International Prostate Symptom Score (IPSS, MD=-5.57, 95%CI: -7.98~-3.16,P<0.00001), nocturia(MD=-0.7, 95%CI: -1.16~-0.24,P=0.003), residual urine rate(MD=-6.97;95%CI: -12.57~-1.37,P=0.01), average flow rate(MD=2.04;95%CI: 0.52~3.56,P=0.008), and maximum flow rate (MD=4.29;95%CI: 0.58~8.01,P=0.02)of patients. However, there was no significant difference in the residual urine volume(MD=-35.93;95%CI: -78.62~6.76,P=0.10)between pre-treatment and post-treatment groups. Conclusion: Urapidil is an effective medication for relieving LUTS in BPH patients. However, due to the limited quantity and quality of current RCT studies, high-quality and large-scale RCT studies are still needed to further confirm this conclusion. |
---|---|
MeSH term(s) | Male ; Humans ; Prostatic Hyperplasia/complications ; Prostatic Hyperplasia/drug therapy ; Lower Urinary Tract Symptoms/drug therapy ; Lower Urinary Tract Symptoms/etiology ; Piperazines ; Randomized Controlled Trials as Topic ; Observational Studies as Topic |
Chemical Substances | urapidil (A78GF17HJS) ; Piperazines |
Language | Chinese |
Publishing date | 2024-04-11 |
Publishing country | China |
Document type | Meta-Analysis ; Systematic Review ; English Abstract ; Journal Article |
ZDB-ID | 2267480-9 |
ISSN | 1009-3591 |
ISSN | 1009-3591 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 6577: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.